Search Result

Results for "

instability

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (1) Akt (2) Antibiotic (2) ATM/ATR (2) Bacterial (3) Biochemical Assay Reagents (2) Calcium Channel (1) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (6) FKBP (1) GCGR (2) Glutathione Peroxidase (1) Isotope-Labeled Compounds (1) JNK (2) Kinesin (1) mAChR (1) MDM-2/p53 (1) MEK (2) Microtubule/Tubulin (2) MMP (2) Opioid Receptor (1) Potassium Channel (1) Reference Standards (1)
By Research Areas:	Cancer (12) Infection (3) Inflammation/Immunology (2) Metabolic Disease (2) Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100504

S-methyl DM1	Microtubule/Tubulin ADC Payload	Cancer
S-methyl DM1 is a thiomethyl derivative of Maytansine. S-methyl DM1 binds to tubulin with a K_d of 0.93 μM and inhibts microtubule polymerization. S-methyl DM1 potently suppresses microtubule dynamic instability and has anticancer effects .

HY-151165

LasR-IN-3	Antibiotic Bacterial	Infection
LasR-IN-3 is a LasR inhibitor against Pseudomonas aeruginosa. LasR-IN-3 induces LasR structure instability and completely dissociates LasR functioning dimeric form .

HY-W199190

2-CEES	DNA/RNA Synthesis	Cancer
2-CEES is a mustard gas analog forms only DNA monoadducts. 2-CEES induces centrosome amplification in human and mouse cells. 2-CEES induces centrosome amplification and chromosome instability .

HY-W143531

Perfluorohexyloctane NOV03; SHR8058	Biochemical Assay Reagents	Inflammation/Immunology
Perfluorohexyloctane (NOV03), a semifluorinated alkane, reduces tear film instability in Meibomian gland dysfunction and evaporative dry eye disease. Perfluorohexyloctane is a long-term tamponade agent. Perfluorohexyloctane increases tear film breakup time and lipid layer thickness .

HY-163941

GSK_WRN2	DNA/RNA Synthesis	Cancer
GSK_WRN2 is a potent and selective covalent WRN helicase inhibitor that suppresses replication stress caused by DNA (TA)_n dinucleotide repeat expansions. GSK_WRN2 can be used to study microsatellite instability (MSI) cancers .

HY-124325

PIP-199	DNA Alkylator/Crosslinker	Cancer
PIP-199 is a selective inhibitor of *RMI (RecQ-mediated genome instability* protein) core complex/MM2 interaction, with an IC₅₀** of 36 μM. PIP-199 can be used for the research of sensitizing resistant tumors to DNA crosslinking chemotherapeutics .

HY-174217

WRN-IN-19	DNA/RNA Synthesis	Cancer
WRN-IN-19 (Compound (S)-27) is a covalent WRN helicase inhibitor, with pIC50 (0 h/4 h) = 5.4/7.5 in the DNA-unwinding 5 endpoint assays. WRN-IN-19 shows synthetic lethality in MSI-H (high microsatellite instability) cancer cells .

HY-P6053

KK-103	Opioid Receptor	Neurological Disease
KK-103 is a precursor of leucine-enkephalin (Leu-ENK) overcomes high proteolytic instability of Leu-ENK via markedly increased plasma stability in mice that has antinociceptive effect .

HY-16489

Terodiline	Potassium Channel mAChR Calcium Channel	Metabolic Disease
Terodiline, an antispasmodic agent, blocks hERG current with the IC₅₀ of 375 nM. Terodiline has both anticholinergic and calcium antagonist properties, and effectively reduces abnormal bladder contractions caused by detrusor instability. Terodiline can be used for the research of urinary incontinence .

HY-144723

Antitubercular agent-13	Bacterial	Infection
Antitubercular agent-13 (Compound 3d) is an antitubercular agent with MIC values of 0.007 µg/mL and 1.851 µg/mL against MTB H37Rv and MDR-MTB 16833, respectively. Antitubercular agent-13 shows metabolic instability .

HY-169422

GSK4418959 IDE275	DNA/RNA Synthesis	Cancer
GSK4418959 (IDE275) is a non-covalent, reversible, selective and orally active WRN helicase inhibitor. GSK4418959 inhibits ATPase and DNA unwinding functions in an ATP-competitive manner. GSK4418959 can be used for the study of microsatellite instability-high (MSI-H) cancer .

HY-156581

WRN inhibitor 5	DNA/RNA Synthesis	Cancer
WRN inhibitor 5, a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 5 can be used for the research of cancer, including cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair system (dMMR) .

HY-P0119

Lixisenatide 2 Publications Verification	GCGR MEK Akt MMP JNK	Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^−/− Irs ^2+/− mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

HY-158116

VVD-214 RO7589831; VVD-133214	DNA/RNA Synthesis	Cancer
VVD-214 is a synthetic lethal allosteric inhibitor of WRN helicase with an IC₅₀ of 0.1316 µM. VVD-214 covalently binds to cysteine 727 of WRN and inhibits ATP hydrolysis and helicase activity. VVD-214 is potent in causing double-stranded DNA breaks, nuclear swelling, and cell death in high microsatellite instability (MSI) cancers .

HY-112210

Shield-1 5+ Cited Publications Shld1	FKBP	Others
Shield-1 (Shld1) is a specific, cell-permeant and high-affinity ligand of FK506-binding protein-12 (FKBP), and reverses the instability by binding to mutated FKBP (mtFKBP), allowing conditional expression of mtFKBP-fused proteins. Shield-1 can stabilize proteins tagged with a mutated FKBP12-derived destabilization domain (DD) .

HY-137864

Amifostine thiol 1 Publications Verification WR-1065	MDM-2/p53	Cancer
Amifostine thiol (WR-1065) is an active metabolite of the cytoprotector Amifostine (HY-B0639). Amifostine thiol is a cytoprotective agent with radioprotective abilities. Amifostine thiol activates p53 through a JNK-dependent signaling pathway .

HY-162110

AM-9022	Kinesin Microtubule/Tubulin	Cancer
AM-9022 is an orally active, potent, selective KIF18A inhibitor that can be used for research on cancer .

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA	Isotope-Labeled Compounds GCGR MEK Akt MMP JNK	Neurological Disease
Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^?/? Irs ^2+/? mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

HY-W127709

Chlorophyll b	Biochemical Assay Reagents Glutathione Peroxidase	Others
Chlorophyll b is an orally active tetrapyrrole derivative and pigment. Chlorophyll b can be obtained from photosynthetic organisms such as plants and algae. Chlorophyll b acts as a hydrogen donor and increases Glutathione levels. Chlorophyll b has antioxidant activity and functionally replaces chlorophyll a in photosystem II to participate in photosynthesis. Chlorophyll b reduces Cisplatin (HY-17394)-induced DNA damage, chromosome instability, and oxidative stress. Chlorophyll b is mainly used in the study of plant photosynthesis mechanism .

HY-101566A

Elimusertib hydrochloride Maximum Cited Publications 11 Publications Verification BAY 1895344 hydrochloride	ATM/ATR	Cancer
Elimusertib (BAY 1895344) hydrochloride is a potent, orally active and selective ATR inhibitor with an IC₅₀ of 7 nM. Elimusertib hydrochloride has anti-tumor activity . Elimusertib hydrochloride can be used for the research of solid tumors and lymphomas .

HY-151165R

LasR-IN-3 (Standard)	Reference Standards Antibiotic Bacterial	Infection
Quinizarin (Standard) is the analytical standard of Quinizarin. This product is intended for research and analytical applications. Quinizarin (1,4-Dihydroxyanthraquinone), a part of the anticancer agents such as Doxorubicin, Daunorubicin, and Adriamycin, interacts with DNA by intercalating mode (Kd=86.1 μM). Quinizarin is used as a fungicide and pesticide chemical and has shown the ability to inhibit tumor cell growth .

HY-101566

Elimusertib Maximum Cited Publications 11 Publications Verification BAY 1895344	ATM/ATR	Cancer
Elimusertib (BAY-1895344) is a potent, orally active and selective ATR inhibitor with an IC₅₀ of 7 nM. Elimusertib has anti-tumor activity . Elimusertib can be used for the research of solid tumors and lymphomas .

Cat. No.	Product Name

HY-L085

Anti-Parkinson's Disease Compound Library	1,693 compounds
Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD. MCE offers a unique collection of 1,693 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

Anti-Parkinson's Disease Compound Library

1,693 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 1,693 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

HY-L034

Anti-Aging Compound Library	5,983 compounds
Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. MCE Anti-Aging Compound Library contains 5,983 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

Anti-Aging Compound Library

5,983 compounds

Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.

MCE Anti-Aging Compound Library contains 5,983 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

Cat. No.	Product Name	Type

HY-W127709

Chlorophyll b	Biochemical Assay Reagents
Chlorophyll b is an orally active tetrapyrrole derivative and pigment. Chlorophyll b can be obtained from photosynthetic organisms such as plants and algae. Chlorophyll b acts as a hydrogen donor and increases Glutathione levels. Chlorophyll b has antioxidant activity and functionally replaces chlorophyll a in photosystem II to participate in photosynthesis. Chlorophyll b reduces Cisplatin (HY-17394)-induced DNA damage, chromosome instability, and oxidative stress. Chlorophyll b is mainly used in the study of plant photosynthesis mechanism .

Chlorophyll b

Biochemical Assay Reagents

Chlorophyll b is an orally active tetrapyrrole derivative and pigment. Chlorophyll b can be obtained from photosynthetic organisms such as plants and algae. Chlorophyll b acts as a hydrogen donor and increases Glutathione levels. Chlorophyll b has antioxidant activity and functionally replaces chlorophyll a in photosystem II to participate in photosynthesis. Chlorophyll b reduces Cisplatin (HY-17394)-induced DNA damage, chromosome instability, and oxidative stress. Chlorophyll b is mainly used in the study of plant photosynthesis mechanism .

Cat. No.	Product Name	Target	Research Area

HY-P0119

Lixisenatide 2 Publications Verification	GCGR MEK Akt MMP JNK	Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^−/− Irs ^2+/− mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

HY-P6053

KK-103	Opioid Receptor	Neurological Disease
KK-103 is a precursor of leucine-enkephalin (Leu-ENK) overcomes high proteolytic instability of Leu-ENK via markedly increased plasma stability in mice that has antinociceptive effect .

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA	Isotope-Labeled Compounds GCGR MEK Akt MMP JNK	Neurological Disease
Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^?/? Irs ^2+/? mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

Cat. No.	Product Name	Chemical Structure

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA
Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^?/? Irs ^2+/? mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

Lixisenatide (Leu-13C6,15N) TFA

Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^?/? Irs ^2+/? mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.